New hope for stomach bug: study tests faster, stronger treatments

NCT ID NCT06349486

Recruiting now Disease control Sponsor: Kaohsiung Medical University Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study compares three different 14-day treatments for Helicobacter pylori, a bacteria that can cause stomach ulcers and cancer. About 390 adults with H. pylori infection will receive either a new triple therapy with bismuth, amoxicillin, and vonoprazan; a dual therapy with vonoprazan and amoxicillin; or a standard triple therapy with rabeprazole. The goal is to see which treatment works best and is safest, while also looking at how antibiotic resistance and genetics affect success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI ERADICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kaohsiung Medical University Hospital
RECRUITING

Kaohsiung City, 807, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HELICOBACTER PYLORI ERADICATION